New article published today by @ClaraMosq on new #MachineLearning #algorithm to automatically detect meals and estimate size of meal for use within fully automated insulin delivery for people with #T1D https://t.co/NxVXpSCFHJ

I have a small request for my medical and paramedical colleagues - please can you take 20 seconds from your day and complete this brief survey. I’m hoping to bring something special to medical practitioners in the furniture….thanks much! https://t.co/pkI0PAfTXY

2023 is our 25th year as a company, a momentous milestone that marks a quarter century of our devotion to science & to patients. We'll be celebrating our 25th by sharing the moments & people that have made us into the company we are today. #Cyto25 https://t.co/FIyBA9tvih

Thanks @nytimes for being my top podcast on @Spotify this year. I loved all 458 minutes of it. #SpotifyWrapped

#HappyThanksgiving from all of us at Cytokinetics! We’re #thankful for a lot, but we’re especially thankful for our amazing team of employees who work hard every day toward our collective goal of improving the lives of patients with diseases of impaired muscle function.

So proud of our #HCM team and our patients. We just evaluated our 50th patient for aficamten, a cardiac myosin inhibitor. & we had a cake with asymmetrical septal hypertrophy, a myectomy and a sarcomere unit - made by the brilliant MLL ( https://t.co/O8eCYJmG1W ) #CardioTwitter

A few weeks ago, we hosted our first annual Cytokinetics Research Day. It was a jam-packed day with excellent presentations from our colleagues in research showcasing their work. We loved taking a dive into the innovative research taking place that powers our continued progress.

Last week we hosted Jillian, a member of our #HCM Patient & Caregiver Advisory Council, at our SSF office. While onsite, Jillian saw firsthand how she & others like her inspire us to do the work that we do. Learn more about HCM and Jillian’s journey here: https://t.co/wEegIb5Anh

We are excited to announce that we have been recognized as one of @FortuneMagazine's Best Workplaces in BioPharma in 2022! #BestWorkplaces We are honored to be a best workplace & are grateful to our wonderful Cytokinetics team. https://t.co/gIf956JkWi

Our paper on the first-in-human study of #aficamten is out with an editorial by Zoltan Papp - thanks to all those that contributed! We are now studying #aficamten in a Phase 3 clinical trial, #SEQUOIAHCM. Privileged to work with wonderful collaborators worldwide #teamwork.

Join us in donating to the @YoseConservancy to protect sequoias threatened by wildfires across CA. Sequoias were chosen as the namesake of our Phase 3 clinical trial SEQUOIA-HCM because they help convey strength and resilience. Learn more here: https://t.co/U2omahHb29

Omecamtiv mecarbil joins bblck, SGLT2i, ARNI, ACE/ARB, MRA as HFrEF pharmacotherapies that improve clin outcomes but not exercise capacity in RCTs. It was an honor to work w/@DukeHFDoc & the entire METEORIC-HF team to rigorously conduct this trial. @MGHHeartHealth @MGHMedicine

The @hcmsociety inaugural scientific sessions will take place on Friday 9/30 in DC Join us (+ @HFSA ) Register here and consider becoming a member https://t.co/rekakwMqnH Abstracts website is now open https://t.co/HkqFqThHvP #CardioTwitter #HCM

HCM Society Inaugural Scientific Sessions - Sep 30th 2022 - SAVE THE DATE and register early! Inaugural Keynote by Dr. Eugene BRAUNWALD - be there and witness history!!! @hcmsociety

We are excited to announce that we have been recognized as one of @FortuneMagazine’s Best Workplaces in the Bay Area in 2022! #100BestCos Thank you to our wonderful team for making Cytokinetics such a great place to work. https://t.co/6EKpNUW0By

Presented at #ASE2022 by Ted Abraham, #echofirst findings from the 10-week on treatment placebo-controlled phase II aficamten in obstructive #HCM (#REDWOOD-HCM). Follow along if you've missed the #ASE2022 presentation #CardioTwitter

Here's today's Imaging Wire https://t.co/hQH7Cyp50H Featuring... @ultromics @Rad_Partners @ARAImaging @radai @FujifilmHealth @annalise_ai @ButterflyNetInc @enlitic @histosonics @GEHealthcare @aidocmed @gleamer_ai @RapidAI @DrRossUpton @JODriscoll9 @malsharqi1 @HeitnerStephen

This is the conclusion slide

Significant reduction in NTproBNP and hsTnI which are favorable to see in #HCM

Significant improvement in NYHA class by 12 and 24 weeks, where ~80% of patients had improvement by 1 NYHA class or more. No worsening in NYHA class, and 21% remained in the same NYHA class (typically class II).